EcoDrugPlus

Cytochrome P450, Family 26, Subfamily A, Polypeptide 1

Ensembl ID : ENSTNIG00000004668
Gene Symbol: CYP26A1
2 Cross references
194 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily C, Polypeptide 4

Ensembl ID : ENSTNIG00000007453
Gene Symbol: CYP3C4
2 Cross references
138 Possible Orthologues:

Cytochrome P450, Family 46, Subfamily A, Polypeptide 1, Tandem Duplicate 4

Ensembl ID : ENSTNIG00000009696
Gene Symbol: CYP46A1.4
2 Cross references
258 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1a

Ensembl ID : ENSTNIG00000017543
Gene Symbol: DGAT1A
2 Cross references
191 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1b

Ensembl ID : ENSTNIG00000018385
Gene Symbol: DGAT1B
2 Cross references
190 Possible Orthologues:

Dihydroorotate Dehydrogenase

Ensembl ID : ENSTNIG00000005752
Gene Symbol: DHODH
2 Cross references
172 Possible Orthologues:

Dihydropyrimidine Dehydrogenase B

Ensembl ID : ENSTNIG00000005550
Gene Symbol: DPYDB
2 Cross references
211 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSTNIG00000013173
Gene Symbol: DDR2
2 Cross references
204 Possible Orthologues:

Dopamine Receptor D1b

Ensembl ID : ENSTNIG00000018218
Gene Symbol: DRD1B
2 Cross references
199 Possible Orthologues:

Dopamine Receptor D2a

Ensembl ID : ENSTNIG00000007779
Gene Symbol: DRD2A
2 Cross references
208 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSTNIG00000012726
Gene Symbol: DRD3
2 Cross references
203 Possible Orthologues:

Dopamine Receptor D4

Ensembl ID : ENSTNIG00000004335
Gene Symbol: DRD4
2 Cross references
180 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).